|Bid||44.00 x 900|
|Ask||46.05 x 800|
|Day's Range||43.83 - 46.42|
|52 Week Range||24.15 - 94.17|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 30, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||82.00|
Atea Pharmaceuticals (AVIR) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
Atea Pharmaceuticals, Inc. ( NASDAQ:AVIR ) shareholders will have a reason to smile today, with the analysts making...